# NRG Therapeutics

**Source:** https://geo.sig.ai/brands/nrg-therapeutics  
**Vertical:** BioTech  
**Subcategory:** Mitochondrial Therapeutics (ALS + Parkinson's)  
**Tier:** Emerging  
**Website:** nrgtherapeutics.com  
**Last Updated:** 2026-04-14

## Summary

Raised £50M ($67M) oversubscribed Series B (Sep 2025). First participants dosed in Phase 1 of NRG5051 (Jan 2026). Phase 1 readout expected end of 2026. Oral small molecules targeting mPTP in ALS and Parkinson's.

## Company Overview

NRG Therapeutics develops first-in-class oral small molecules targeting the mitochondrial permeability transition pore (mPTP) — a protein complex whose aberrant opening triggers the cellular energy failure and neurodegeneration that underlies ALS (amyotrophic lateral sclerosis) and Parkinson's disease. The company raised £50 million ($67 million) in an oversubscribed Series B in September 2025, and dosed the first clinical trial participants for NRG5051 in January 2026, with Phase 1 readout expected by end of 2026.

The mPTP target represents a genuinely new mechanism for neurodegenerative disease: rather than targeting the protein aggregates (tau, alpha-synuclein, TDP-43) that accumulate in neurodegenerative conditions, NRG targets the cellular energy infrastructure failure that these aggregates cause. By stabilizing mPTP function, NRG5051 aims to preserve neuronal energy metabolism that aggregates disrupt — a disease-modifying approach that could apply across multiple neurodegenerative conditions sharing this common pathological mechanism.

The CNS penetrance of NRG5051 is the key pharmacological challenge that makes the oral small molecule approach technically difficult: the blood-brain barrier restricts most compounds from reaching the brain in therapeutic concentrations. NRG's disclosed Phase 1 entry reflects pre-clinical CNS penetrance data that justified regulatory approval for human testing — a hurdle that prevents most mitochondria-targeting compounds from reaching the clinic.

## Frequently Asked Questions

### What does NRG Therapeutics do?
First-in-class oral small molecules targeting the mitochondrial permeability transition pore (mPTP) — addressing the cellular energy failure underlying ALS and Parkinson's. Phase 1 started January 2026.

### How much has NRG raised?
£50M ($67M) oversubscribed Series B in September 2025.

### What is the mPTP mechanism?
Aberrant mPTP opening triggers neuronal energy failure and death. NRG stabilizes mPTP function to preserve neuronal energy metabolism — targeting the cellular machinery failure rather than protein aggregates.

### Why is oral CNS penetrance significant?
The blood-brain barrier blocks most compounds from reaching therapeutic brain concentrations. NRG's oral Phase 1 entry reflects pre-clinical CNS penetrance data sufficient for regulatory clinical trial approval.

### What diseases does NRG Therapeutics target and why mitochondria?
NRG Therapeutics targets ALS (amyotrophic lateral sclerosis) and Parkinson's disease — neurodegenerative diseases characterized by motor neuron and dopaminergic neuron death respectively. Both conditions involve mitochondrial dysfunction as a key pathological mechanism: neurons are among the most metabolically active cells in the body, and failing mitochondria trigger apoptosis and energy deficit that drives neurodegeneration. The mPTP (mitochondrial permeability transition pore) opening is a convergence point for multiple neurodegeneration pathways that NRG's drugs target.

### What is NRG's drug development approach?
NRG Therapeutics develops small molecule mPTP inhibitors — drugs that block the mitochondrial permeability transition pore from opening, preventing the mitochondrial membrane collapse that triggers neuronal death. The company's lead compounds are orally bioavailable and CNS-penetrant, designed to be taken as daily pills by ALS and Parkinson's patients. This is in contrast to other mitochondrial therapies that require IV or intrathecal administration.

### What clinical and regulatory milestones is NRG pursuing?
NRG Therapeutics is in late preclinical development, running mPTP inhibitor efficacy studies in ALS and Parkinson's animal models alongside IND-enabling toxicology studies. The company is targeting FDA Fast Track Designation for its ALS program given the disease's high unmet need and rapid progression. IND filing is targeted for 2025-2026, with a Phase 1 safety study in ALS patients as the initial clinical milestone.

### What is the ALS treatment landscape and where does NRG fit?
ALS has three FDA-approved treatments: riluzole (extends survival 2-3 months, approved 1995), edaravone (modestly slows function decline in a subset), and AMX0035 (Relyvrio, approved 2022, mechanism involving mitochondrial protection). Tofersen (an ASO for SOD1-ALS) was approved in 2023 for a specific genetic subtype. NRG's mPTP inhibitor addresses a mitochondrial mechanism distinct from existing approved drugs and could potentially combine with AMX0035 or Tofersen for additive benefit in appropriate patient populations.

## Tags

healthtech, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*